SARS-CoV-2 envelope protein (Omicron lineage) (E protein)

The SARS-CoV-2 envelope (E) protein is a small, 75-residue hydrophobic membrane protein that acts as a viroporin, essential for viral assembly, budding, and pathogenesis (UniProt P0DTC4). In the Omicron lineage, the E protein is characterized by the T9I mutation, which may influence its ion channel conductance and contribute to the altered virulence profile of the variant (PubMed: 35653330). The protein forms pentameric ion channels in the ER-Golgi intermediate compartment (ERGIC), where it facilitates the transport of calcium ions and triggers the NLRP3 inflammasome. This activation leads to the release of pro-inflammatory cytokines like IL-1β, which is a key driver of the lung injury and systemic inflammation seen in severe COVID-19 cases (PubMed: 32544159). Although no drugs are currently FDA-approved specifically for this target, small molecules such as amantadine and hexamethylene amiloride (HMA) have demonstrated the ability to bind and inhibit the E protein's ion channel activity in vitro (PubMed: 33357440). Targeting the E protein offers a dual therapeutic strategy by potentially reducing viral replication and mitigating the hyper-inflammatory response associated with the infection. The relative conservation of the E protein across variants makes it a promising target for broad-spectrum antiviral development.

Other names

Envelope small membrane proteinsars-cov-2-eViroporin EE proteinSARS-CoV-2 E protein

Inhibition of viroporin ion channel activity and disruption of viral assembly and budding processes.